A statistical framework for assessing pharmacological response and biomarkers using uncertainty estimates
- University of Sheffield, United Kingdom
- PROWLER.io, United Kingdom
- Helmholtz Zentrum Muenchen, Germany
- AstraZeneca, United States
- Heidelberg University, Germany
- Wellcome Sanger Institute, United Kingdom
- Helmholtz Zentrum München, Germany
- Lancaster University, United Kingdom
Abstract
High-throughput testing of drugs across molecular-characterised cell lines can identify candidate treatments and discover biomarkers. However, the cells' response to a drug is typically quantified by a summary statistic from a best-fit dose-response curve, whilst neglecting the uncertainty of the curve fit and the potential variability in the raw readouts. Here, we model the experimental variance using Gaussian Processes, and subsequently, leverage uncertainty estimates to identify associated biomarkers with a new Bayesian framework. Applied to in vitro screening data on 265 compounds across 1,074 cancer cell lines, our models identified 24 clinically established drug response biomarkers, and provided evidence for 6 novel biomarkers by accounting for association with low uncertainty. We validated our uncertainty estimates with an additional drug screen of 26 drugs, 10 cell lines with 8 to 9 replicates. Our method is applicable to any dose-response data without replicates, and improves biomarker discovery for precision medicine.
Data availability
All data is available through the GDSC downloads portal (ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases)Raw dose response data have been deposited in GDSC under v17a_public_raw_data.csvSigmoid fitted dose-response curves have been deposited in GDSC under v17_fitted_dose_response.csvCell line genomics data have been deposited in GDSC under GDSCtools_mobems.zipCell line identity details have been deposited in GDSC under Cell_Lines_Details.xlsxDrug compound details have been been deposited in GDSC under screened_compunds_rel_8.2.csv
Article and author information
Author details
Funding
NIHR Sheffield Biomedical Research Centre (BRC - IS-BRC-1215-20017)
- Dennis Wang
- Tzen S Toh
Rosetrees Trust (A2501)
- Dennis Wang
- Tzen S Toh
Academy of Medical Sciences (SBF004/1052)
- Dennis Wang
Wellcome Trust (206194)
- Mathew J Garnett
European Union's Horizon 2020 Research and Innovation Programme (Grant agreement No. 950293 - COMBAT-RES)
- Michael P Menden
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2020, Wang et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,831
- views
-
- 331
- downloads
-
- 20
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
A statistical framework for assessing pharmacological response and biomarkers using uncertainty estimates
eLife 9:e60352.
https://doi.org/10.7554/eLife.60352
Further reading
-
- Computational and Systems Biology
- Evolutionary Biology
As pathogens spread in a population of hosts, immunity is built up, and the pool of susceptible individuals are depleted. This generates selective pressure, to which many human RNA viruses, such as influenza virus or SARS-CoV-2, respond with rapid antigenic evolution and frequent emergence of immune evasive variants. However, the host’s immune systems adapt, and older immune responses wane, such that escape variants only enjoy a growth advantage for a limited time. If variant growth dynamics and reshaping of host-immunity operate on comparable time scales, viral adaptation is determined by eco-evolutionary interactions that are not captured by models of rapid evolution in a fixed environment. Here, we use a Susceptible/Infected model to describe the interaction between an evolving viral population in a dynamic but immunologically diverse host population. We show that depending on strain cross-immunity, heterogeneity of the host population, and durability of immune responses, escape variants initially grow exponentially, but lose their growth advantage before reaching high frequencies. Their subsequent dynamics follows an anomalous random walk determined by future escape variants and results in variant trajectories that are unpredictable. This model can explain the apparent contradiction between the clearly adaptive nature of antigenic evolution and the quasi-neutral dynamics of high-frequency variants observed for influenza viruses.
-
- Computational and Systems Biology
- Medicine
Sudden death after myocardial infarction (MI) is associated with electrophysiological heterogeneities and ionic current remodelling. Low ejection fraction (EF) is used in risk stratification, but its mechanistic links with pro-arrhythmic heterogeneities are unknown. We aim to provide mechanistic explanations of clinical phenotypes in acute and chronic MI, from ionic current remodelling to ECG and EF, using human electromechanical modelling and simulation to augment experimental and clinical investigations. A human ventricular electromechanical modelling and simulation framework is constructed and validated with rich experimental and clinical datasets, incorporating varying degrees of ionic current remodelling as reported in literature. In acute MI, T-wave inversion and Brugada phenocopy were explained by conduction abnormality and local action potential prolongation in the border zone. In chronic MI, upright tall T-waves highlight large repolarisation dispersion between the border and remote zones, which promoted ectopic propagation at fast pacing. Post-MI EF at resting heart rate was not sensitive to the extent of repolarisation heterogeneity and the risk of repolarisation abnormalities at fast pacing. T-wave and QT abnormalities are better indicators of repolarisation heterogeneities than EF in post-MI.
